Management Team

34.jpg 35.jpg
  • Scientific Founder

    Scientific Founder

    Dr. Dong is an academician of the Chinese Academy of Sciences. He is also Chair Professor and Vice President at Westlake University, as well as the Dean of Westlake University School of Medicine, Dr. Dong served as a Professor of Immunology and the Director of the Center for inflammation and Cancer at the University of Texas MD Anderson Cancer Center before his move to China. He was Dean of Tsinghua University School of Medicine and Director at the Institute for Immunology at Tsinghua University, and also was Professor at Shanghai Jiao Tong University School of Medicine and Director for the Shanghai Immune Therapy Institute.

    Dr. Dong’s research is to understand the molecular mechanisms whereby immune and inflammatory responses are normally regulated, and to apply this knowledge to the understanding and treatment of infection, autoimmunity and allergy disorders as well as cancer. The work from Dr. Dong’s group has led to the discoveries of Th17 and T follicular helper (Tfh) cell subsets in the immune system and elucidation of their biological and pathological functions.

    a3_img02.jpg

    Chen Dong, Ph.D.

    Scientific Founder & Chief Scientific Advisor

  • Management Team

    Management Team

    Dr. Guo Xiaoning has over 20 years of extensive experience in the field of biopharmaceuticals and R&D. This includes more than a decade of expertise in clinical development and portfolio management at multinational pharmaceutical companies as well as global CRO for R&D.

    Prior to joining Bennubio, Dr. Guo Xiaoning held key positions including CMO at Neurophth, VP & Head of R&D, CMO at SciClone, DGM & CMO at Jiaochen Bio, respectively. The roles involve overseeing the development and life cycle management of multiple innovative drug pipelines, leading the team's R&D products towards global expansion and commercialization.

    Earlier in his career, he gained valuable experiences working for AstraZeneca, Johnson & Johnson, and Covens by assisting these companies in formulating dual reporting policies between the US and Australia. He successfully led numerous global research projects on new drugs development and clinical trials while introducing several domestic innovative drugs to the market.

    a3img01.jpg

    Xiaoning Guo, Ph.D.

    Co-Founder & CEO